The prognostic and predictive potential of CAV1/2 expression was analysed in the GeparSepto trial (GBG 069).
GBG will present several posters at the San Antonio Breast Cancer Symposium 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
